{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:46:25Z","timestamp":1791895585381,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Almirall S.A."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s13555-025-01526-8","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T16:07:48Z","timestamp":1756397268000},"page":"3285-3300","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Sarecycline in Chinese Patients with Moderate-to-Severe Acne Vulgaris: Randomized Phase 3 Clinical Trial with Open-Label Follow-Up"],"prefix":"10.1007","volume":"15","author":[{"given":"Jianzhong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belchin","family":"Kostov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Cabedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tolga","family":"Baykal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garc\u00eda Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"1526_CR1","first-page":"63","volume":"21","author":"M Ramos-e-Silva","year":"2009","unstructured":"Ramos-e-Silva M, Carneiro SC. Acne vulgaris: review and guidelines. Dermatol Nurs. 2009;21:63\u20138 (quiz 69).","journal-title":"Dermatol Nurs"},{"key":"1526_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.19106\/JMedScie004604201403","volume":"46","author":"AD Sulistyowati","year":"2014","unstructured":"Sulistyowati AD, Adiwinarni DR, Etnawati K. The relationship between serum malondialdehyde levels and severity of acne vulgaris on male. J Med Sci (Berkala Ilmu Kedokteran). 2014;46:167\u201373.","journal-title":"J Med Sci (Berkala Ilmu Kedokteran)"},{"key":"1526_CR3","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40257-014-0099-z","volume":"15","author":"S Das","year":"2014","unstructured":"Das S, Reynolds RV. Recent advances in acne pathogenesis: implications for therapy. Am J Clin Dermatol. 2014;15:479\u201388.","journal-title":"Am J Clin Dermatol"},{"key":"1526_CR4","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/S0140-6736(98)01046-0","volume":"351","author":"SK Brown","year":"1998","unstructured":"Brown SK, Shalita AR. Acne vulgaris. Lancet. 1998;351:1871\u20136.","journal-title":"Lancet"},{"key":"1526_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/jdv.14374","volume":"31","author":"B Dr\u00e9no","year":"2017","unstructured":"Dr\u00e9no B. What is new in the pathophysiology of acne, an overview. J Eur Acad Dermatol Venereol. 2017;31:8\u201312.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1526_CR6","first-page":"1","volume":"29","author":"HPM Gollnick","year":"2015","unstructured":"Gollnick HPM. From new findings in acne pathogenesis to new approaches in treatment. J Eur Acad Dermatol Venereol. 2015;29:1\u20137.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1526_CR7","doi-asserted-by":"publisher","first-page":"e01297","DOI":"10.1128\/AAC.01297-18","volume":"63","author":"G Zhanel","year":"2019","unstructured":"Zhanel G, Critchley I, Lin L-Y, Alvandi N. Microbiological profile of sarecycline, a novel targeted spectrum tetracycline for the treatment of acne vulgaris. Antimicrob Agents Chemother. 2019;63:e01297-e1318.","journal-title":"Antimicrob Agents Chemother"},{"key":"1526_CR8","doi-asserted-by":"publisher","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","volume":"90","author":"RV Reynolds","year":"2024","unstructured":"Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90:1006.e1-1006.e30.","journal-title":"J Am Acad Dermatol"},{"key":"1526_CR9","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/JD9.0000000000000043","volume":"2","author":"Chinese Guidelines for the Management of Acne Vulgaris","year":"2019","unstructured":"Chinese Guidelines for the Management of Acne Vulgaris. 2019 Update #. Int J Dermatol Venereol. 2019;2:129\u201338.","journal-title":"Int J Dermatol Venereol"},{"key":"1526_CR10","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.jaad.2015.12.037","volume":"74","author":"AL Zaenglein","year":"2016","unstructured":"Zaenglein AL, Pathy AL, Schlosser BJ, Alikhan A, Baldwin HE, Berson DS, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74:945-973.e33.","journal-title":"J Am Acad Dermatol"},{"key":"1526_CR11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1060028019873111","volume":"54","author":"W Haidari","year":"2020","unstructured":"Haidari W, Bruinsma R, Cardenas-de La Garza JA, Feldman SR. Sarecycline Review. Ann Pharmacother. 2020;54:164\u201370.","journal-title":"Ann Pharmacother"},{"key":"1526_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2217\/fmb-2019-0199","volume":"14","author":"AY Moore","year":"2019","unstructured":"Moore AY, Charles JEM, Moore S. Sarecycline: a narrow spectrum tetracycline for the treatment of moderate-to-severe acne vulgaris. Future Microbiol. 2019;14:1235\u201342.","journal-title":"Future Microbiol"},{"key":"1526_CR13","unstructured":"Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs. Products. New Drug Application (NDA): 209521. Company: Almirall. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=209521. Accessed Apr 2024."},{"key":"1526_CR14","unstructured":"Center for Drug Evaluation and Research; US Food and Drug Administration. Advancing health through innovation: 2018 new drug therapy approvals. Published 2018. https:\/\/www.fda.gov\/media\/120357\/download. Accessed April 2024."},{"key":"1526_CR15","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/antibiotics11030324","volume":"11","author":"M Ghannoum","year":"2022","unstructured":"Ghannoum M, Long L, Bunick C, Del Rosso J, Gamal A, Tyring S, et al. Sarecycline demonstrated reduced activity compared to minocycline against microbial species representing human gastrointestinal microbiota. Antibiotics. 2022;11:324.","journal-title":"Antibiotics"},{"key":"1526_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3390\/antibiotics10040439","volume":"10","author":"CG Bunick","year":"2021","unstructured":"Bunick CG, Keri J, Tanaka SK, Furey N, Damiani G, Johnson JL, et al. Antibacterial mechanisms and efficacy of sarecycline in animal models of infection and inflammation. Antibiotics. 2021;10:439.","journal-title":"Antibiotics"},{"key":"1526_CR17","first-page":"987","volume":"17","author":"A Moore","year":"2018","unstructured":"Moore A, Green LJ, Bruce S, Sadick N, Tschen E, Werschler P, et al. Once-daily oral sarecycline 1.5 mg\/kg\/day is effective for moderate to severe acne vulgaris: results from two identically designed, phase 3, randomized, double-blind clinical trials. J Drugs Dermatol JDD. 2018;17:987\u201396.","journal-title":"J Drugs Dermatol JDD."},{"key":"1526_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010089","volume":"12","author":"AY Moore","year":"2023","unstructured":"Moore AY, Hurley K, Moore SA. A post hoc analysis of efficacy data on Sarecycline in Hispanics with acne from two phase 3, multicenter, randomized, double-blind, placebo-controlled clinical trials. Antibiotics. 2023;12: 89.","journal-title":"Antibiotics"},{"key":"1526_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7573\/dic.2021-10-9","volume":"11","author":"C Chiang","year":"2022","unstructured":"Chiang C, Ward M, Gooderham M. Dermatology: how to manage acne in skin of colour. Drugs Context. 2022;11:1\u201310.","journal-title":"Drugs Context"},{"key":"1526_CR20","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15275","author":"A Grada","year":"2022","unstructured":"Grada A, Del Rosso JQ, Graber E, Bunick CG, Stein Gold L, Moore AY, et al. Sarecycline treatment for acne vulgaris: Rationale for weight-based dosing and limited impact of food intake on clinical efficacy. Dermatol Ther [Internet]. 2022. https:\/\/doi.org\/10.1111\/dth.15275.","journal-title":"Dermatol Ther [Internet]"},{"key":"1526_CR21","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1111\/j.1468-3083.2010.03919.x","volume":"25","author":"AC Perkins","year":"2011","unstructured":"Perkins AC, Cheng CE, Hillebrand GG, Miyamoto K, Kimball AB. Comparison of the epidemiology of acne vulgaris among Caucasian, Asian, Continental Indian and African American women. J Eur Acad Dermatol Venereol. 2011;25:1054\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1526_CR22","first-page":"205","volume":"18","author":"JQ Del Rosso","year":"2019","unstructured":"Del Rosso JQ, Stein-Gold L, Lynde C, Tanghetti E, Alexis AF. Truncal acne: a neglected entity. J Drugs Dermatol JDD. 2019;18:205\u20131208.","journal-title":"J Drugs Dermatol JDD"},{"key":"1526_CR23","doi-asserted-by":"publisher","first-page":"20530","DOI":"10.1073\/pnas.2008671117","volume":"117","author":"Z Batool","year":"2020","unstructured":"Batool Z, Lomakin IB, Polikanov YS, Bunick CG. Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome. Proc Natl Acad Sci U S A. 2020;117:20530\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1526_CR24","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/nar\/gkad103","volume":"51","author":"IB Lomakin","year":"2023","unstructured":"Lomakin IB, Devarkar SC, Patel S, Grada A, Bunick CG. Sarecycline inhibits protein translation in Cutibacterium acnes70S ribosome using a two-site mechanism. Nucleic Acids Res. 2023;51:2915\u201330.","journal-title":"Nucleic Acids Res"},{"key":"1526_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/030006059001800204","volume":"18","author":"J Burton","year":"1990","unstructured":"Burton J, The Dermatology Research Group. A placebo-controlled study to evaluate the efficacy of topical tetracycline and oral tetracycline in the treatment of mild to moderate acne. J Int Med Res. 1990;18:94\u2013103.","journal-title":"J Int Med Res"},{"key":"1526_CR26","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jama.1966.03100170107040","volume":"196","author":"RC Savin","year":"1966","unstructured":"Savin RC, Turner MC. Antibiotics and the placebo reaction in acne. JAMA. 1966;196:365\u20137.","journal-title":"JAMA"},{"key":"1526_CR27","first-page":"E53","volume":"12","author":"DM Pariser","year":"2019","unstructured":"Pariser DM, Green LJ, Lain EL, Schmitz C, Chinigo AS, McNamee B, et al. Safety and tolerability of sarecycline for the treatment of acne vulgaris: results from a phase III, multicenter, open-label study and a phase I phototoxicity study. J Clin Aesthetic Dermatol. 2019;12:E53-62.","journal-title":"J Clin Aesthetic Dermatol"},{"key":"1526_CR28","first-page":"333","volume":"17","author":"JJ Leyden","year":"2018","unstructured":"Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol JDD. 2018;17:333\u20138.","journal-title":"J Drugs Dermatol JDD"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01526-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01526-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01526-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T17:17:37Z","timestamp":1761239857000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01526-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01526-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Belchin Kostov, Judit Cabedo and Esther Garc\u00eda Gil are employees of Almirall. Tolga Baykal is a former employee of Almirall. Jianzhong Zhang, Li He, Xue Chen and Ying Tu have received research grants from Almirall.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trial was conducted according to the principals of the Declaration of Helsinki and the International Council on Harmonization Guidelines for Good Clinical Practice. Written informed consent (including consent to publish the photographs) was provided by enrolled patients or their legal representatives.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}